Home> Company News

Sanofi localization project launched in Beijing E-Town

Updated: 2023-06-16

The localization project refers to completing the entire process of product packaging, filling, and assembly production locally. 

Brendan O'Callaghan, vice president of Sanofi's Executive Committee; Olivier Charmeil, executive vice president of Sanofi, officials from the Beijing Municipal Food and Drug Administration; and the Beijing E-Town Administrative Committee, attended the launch ceremony.

111.jpg

Brendan O'Callaghan delivers a speech at the launch  ceremony. [Photo/beijingetown.com.cn]

In his opening speech, Brendan O'Callaghan said Sanofi has built a complete value chain in research and development, production, and other aspects to provide innovative solutions for Chinese patients. Since the establishment of the Beijing office, it has experienced many key milestones. They're particularly grateful for the help from Beijing Municipality and Beijing E-Town, creating a first-class business environment, and helping the Beijing factory become Sanofi's largest insulin injection production base in the Asia-Pacific region. The local production of Cerezyme® is another important milestone in their in-depth development in China and the next stage of modernization.

222.jpg

Olivier Charmeil makes a speech at the launch  ceremony. [Photo/beijingetown.com.cn]

Olivier Charmeil remarked that the Beijing production base is one of the most important sites for Sanofi Group and a reflection of Sanofi's development in China. In the future, the company will continue to increase investment, starting from the launch of the Cerezyme® Localization Project. The goal is to introduce at least 25 innovative products for China between 2020 and 2025, benefiting more Chinese patients. Meanwhile, they actively implement environmental protection measures throughout the operation process, contributing to global carbon peak and carbon neutrality goals.

The launch ceremony was also attended by senior officials from Beijing Municipal Food and Drug Administration and relevant departments of Beijing E-Town, as well as key leaders of Sanofi Group and all employees of the Beijing production base.